Clinical Trial

SG1906 for CLDN18.2-Positive Solid Tumors

Study acronym: CSG-1906-101
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients with CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-05-04; most recent amendment 2026-07-09.
Trial Details
NCT Number NCT05857332
Lead Sponsor Hangzhou Sumgen Biotech Co., Ltd.
Conditions Locally Advanced Unresectable or Metastatic Solid Tumors
Enrollment 60 participants
Start Date 2023-05-30
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11